Brief: Tryngolza Recommended For Approval In The EU By CHMP For Familial Chylomicronemia Syndrome
25/07/2025 12:16
July 25 (Reuters) - Ionis Pharmaceuticals Inc IONS.O: TRYNGOLZA® (OLEZARSEN) RECOMMENDED FOR APPROVAL IN THE EU BY CHMP FOR FAMILIAL CHYLOMICRONEMIA SYNDROME (FCS) IONIS PHARMACEUTICALS INC - EUROPEAN COMMISSION DECISION EXPECTED BY Q4 2025 Source text: ID:nBw2qdwlxa Further company coverage: IONS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ionis Pharmaceuticals
See all newsAnalysis: US prices for new drugs fell in 2025 as fewer costly gene therapies were launched
Brief: Ionis Announces License Agreement With Recordati For Zilganersen In Alexander Disease (Axd) In All Countries Outside The U.S.
Brief: Ionis Pharmaceuticals Says FDA Approved Tryngolza For Severe Hypertriglyceridemia
Brief: FDA Approves Treatment To Reduce Risk Of Acute Pancreatitis In Adults With Severe Hypertriglyceridemia
Brief: Ionis Announces Appointment Of Ludwig Hantson, Ph.D. To Board Of Directors